1. Targeted therapy based on cellular molecular targets is the most important clinical progress in advanced lung cancer in recent years. Among them, EGFR mutation and ALK rearrangement are the main targets, and gefitinib (ERSA), erlotinib (Troche), crizotinib, etc. are the main drugs. 2.For specific groups of advanced lung cancer (Asian, female, adenocarcinoma, non-smoker), with higher EGFR mutation rate, they are more likely to benefit from molecular targeted therapy treatment, with first treatment efficiency of 50-80%. 3. At second and third line treatment, targeted drugs are beneficial to specific populations (relative to placebo), with a slightly better trend for gefitinib than erlotinib. 4.In second-line treatment, the efficacy of targeted drugs is not inferior to chemotherapy, and the specific population does not get more benefit from this treatment (relative to chemotherapy). 5. In first-line treatment, for patients with EGFR mutation, targeted drugs are significantly better than chemotherapy in tumor control. 6. For specific patient populations, maintenance therapy with targeted drugs after first-line chemotherapy can be considered. 7. Targeted drugs are not recommended to be used as adjuvant therapy after lung cancer surgery. Note: First-line treatment refers to the initial treatment plan for advanced lung cancer. Second-line treatment refers to the second treatment plan after the failure of only one line, and so on. Adjuvant therapy, refers to the treatment taken after radical surgery.